196 related articles for article (PubMed ID: 15803774)
1. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Jakesz R
MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
[No Abstract] [Full Text] [Related]
2. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
3. Cancer: some reasons to be hopeful.
Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
[No Abstract] [Full Text] [Related]
4. Long-term outcomes of aromatase inhibition for breast cancer.
Toi M
Lancet Oncol; 2008 Jan; 9(1):8-10. PubMed ID: 18177815
[No Abstract] [Full Text] [Related]
5. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
6. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
7. [Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Aumiller J
MMW Fortschr Med; 2005 Mar; 147(10):4-6. PubMed ID: 15803773
[No Abstract] [Full Text] [Related]
8. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
9. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
10. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
11. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Johnston SR
Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
[No Abstract] [Full Text] [Related]
12. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
13. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
14. Current developments in hormonal therapy of breast cancer.
Buzdar AU
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
[No Abstract] [Full Text] [Related]
15. Tamoxifen therapy for patients with breast cancer.
Litton J; Buzdar A; Mac Gregor MC; Gonzalez-Angulo A; Hortobagyi G
Lancet; 2013 Jun; 381(9883):2077-8. PubMed ID: 23769223
[No Abstract] [Full Text] [Related]
16. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
17. [Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Aumiller J
MMW Fortschr Med; 2006 Mar; 148(12):4-6, 8. PubMed ID: 16625995
[No Abstract] [Full Text] [Related]
18. Anastrozole data show continued delay in relapse, but no clear survival advantage.
Travis K
J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
[No Abstract] [Full Text] [Related]
19. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Dixon JM
Expert Rev Anticancer Ther; 2006 Jun; 6(6):849-59. PubMed ID: 16761928
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
